Oscillatory Versus Non-Oscillatory Nasal Continuous Airway Pressure Neonatal Respiratory Support
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Madera, California, United States, 93636
- Valley Children's Healthcare
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah Health Sciences Center
-
Salt Lake City, Utah, United States, 84113
- Primary Children's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Newborn (0-28 days of age) admitted to Neonatal Intensive Care Unit (NICU)
- Ordered respiratory treatment of NCPAP
Exclusion Criteria:
- Major congenital defect
- Known or suspected chromosomal disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Nasal CPAP
Standard Nasal CPAP
|
NCPAP is delivered via nasal prongs placed into infant's nares.
It may be delivered via ventilator or by bubble.
|
|
Active Comparator: Oscillatory NCPAP
NCPAP will be given to infant via prongs in the infant's nose.
A Bird Industries pneumatic oscillating diaphragm to drive a Bird Industries phasatron which is attached by T-connector to the NCPAP patient circuit.
|
Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physiologic respiratory stability of Oscillating versus Non-Oscillating NCPAP
Time Frame: 2 months
|
Determine the physiologic respiratory stability (pCO2, respiratory rate, apnea frequency) during treatment with NCPAP
|
2 months
|
|
Need for mechanical ventilation following the initiation of NCPAP.
Time Frame: 2 months
|
The rate of mechanical ventilation following both Oscillating and Non-Oscillating groups.
|
2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total duration of non-invasive and invasive respiratory support in each study group.
Time Frame: 2 months
|
Determine the total duration of non-invasive and invasive respiratory support in each study group.
|
2 months
|
|
total amount of oxygen exposure in each study group. Total amount of oxygen exposure in each study group.
Time Frame: 2 months
|
Determine the total amount of oxygen exposure in each study group.
|
2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Donald Null, MD, University of Utah
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 36738
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.